In older adults with diabetes, GLP-1 receptor agonists were tied to a slightly lower risk for depression compared with one ...

Data from the Phase III EMERGE trial show treatment with Symbravo provided more rapid and sustained migraine relief with ...

The global Heart Failure Drugs Market is valued at $8.6 billion in 2024 and is projected to reach a value of $21.4 billion by 2035. This growth represents a Compound Annual Growth Rate (CAGR) of 12.1% ...